enow.com Web Search

  1. Ads

    related to: sglt2 inhibitors with cardiovascular benefits

Search results

  1. Results from the WOW.Com Content Network
  2. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

  3. Drugs like Ozempic may help lower 2nd stroke, heart attack risk

    www.aol.com/drugs-ozempic-may-help-lower...

    A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...

  4. Type 2 diabetes drugs could lower dementia, Parkinson's ... - AOL

    www.aol.com/type-2-drugs-could-lower-133000670.html

    The analysis showed that over a follow-up period of an average of 2.06 years for people on SGLT2 inhibitors, and 3.70 years for people on different antidiabetes drugs, there was a reduction in the ...

  5. Canagliflozin - Wikipedia

    en.wikipedia.org/wiki/Canagliflozin

    Evidence shows that apart from positive effects on glycemic levels, canagliflozin also reduces the risk of heart attacks and heart failures. [14] SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the ...

  6. Sotagliflozin - Wikipedia

    en.wikipedia.org/wiki/Sotagliflozin

    Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1] It is taken by mouth. [1] The most common side effect is genital infection in women. [2]

  7. A Common Drug Could Lower Your Dementia Risk By 35 ... - AOL

    www.aol.com/common-drug-could-lower-dementia...

    People who took SGLT-2 inhibitors for longer periods of time seemed to have the best results. “SGLT-2 inhibitors might prevent dementia, providing greater benefits with longer treatment,” the ...

  8. Empagliflozin - Wikipedia

    en.wikipedia.org/wiki/Empagliflozin

    Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood.

  9. 4 Ways to Prevent Muscle Loss on Ozempic & Other Weight ... - AOL

    www.aol.com/4-ways-prevent-muscle-loss-115800184...

    Other diabetes drugs, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, can also lead to a reduction in lean mass. This includes canagliflozin (Invokana®) and dapagliflozin (Farxiga®).

  1. Ads

    related to: sglt2 inhibitors with cardiovascular benefits